目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
2.2.2 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS
2.2.3 TOP-DOWN APPROACH
2.2.4 BOTTOM-UP APPROACH
2.2.5 PRIMARY INTERVIEWS
2.3 GROWTH FORECAST MODEL
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 SUPPOSITORIES MARKET OVERVIEW
4.2 NORTH AMERICA: SUPPOSITORIES MARKET, BY TYPE AND COUNTRY
4.3 SUPPOSITORIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
4.4 SUPPOSITORIES MARKET, BY BASE, 2025 VS. 2030 (USD MILLION)
4.5 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2025 VS. 2030 (USD MILLION)
4.6 SUPPOSITORIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of acute and chronic disorders
5.2.1.2 Booming geriatric population worldwide
5.2.1.3 Pharmacokinetic advantages of suppositories
5.2.1.4 Growing demand for targeted and localized drug delivery solutions
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory requirements
5.2.2.2 Rapid development of innovative drug delivery technologies
5.2.2.3 Low patient and caregiver acceptance
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging formulations and 3D techniques
5.2.3.2 Expanding therapeutic applications
5.2.4 CHALLENGES
5.2.4.1 Complex formulation and drug delivery
5.2.4.2 Limited shelf life of suppositories
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 INVESTMENT AND FUNDING SCENARIO
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 3D printed multi-drug-loaded suppositories
5.8.1.2 Self-microemulsifying suppository systems
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 Mucoadhesive and bioadhesive polymers
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Form-fill-seal (FFS) machine technology
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS FOR SUPPOSITORIES
5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS
5.10 TRADE ANALYSIS
5.10.1 IMPORT DATA
5.10.2 EXPORT DATA
5.11 KEY CONFERENCES AND EVENTS, 2025-2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY FRAMEWORK
5.12.1.1 North America
5.12.1.1.1 US
5.12.1.1.2 Canada
5.12.1.2 Europe
5.12.1.2.1 Germany
5.12.1.2.2 Italy
5.12.1.2.3 France
5.12.1.2.4 UK
5.12.1.3 Asia Pacific
5.12.1.3.1 China
5.12.1.3.2 Japan
5.12.1.3.3 India
5.12.1.3.4 South Korea
5.12.1.3.5 Australia
5.12.1.4 Latin America
5.12.1.5 Middle East & Africa
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA
5.15 UNMET NEEDS/END-USER EXPECTATIONS
5.16 IMPACT OF AI/GEN AI
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF AI ON SUPPOSITORIES MARKET
5.16.3 AI USE CASES
5.16.4 FUTURE OF GENERATIVE AI IN SUPPOSITORIES MARKET
5.17 IMPACT OF 2025 US TARIFF
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 IMPACT ON COUNTRY/REGION
5.17.5 IMPACT ON END-USER INDUSTRIES

6 SUPPOSITORIES MARKET, BY TYPE
6.1 INTRODUCTION
6.2 RECTAL SUPPOSITORIES
6.2.1 EASE OF USE, AFFORDABILITY, AND QUICK RELIEF TO PROMOTE GROWTH
6.3 VAGINAL SUPPOSITORIES
6.3.1 SHORT-TERM THERAPY AND QUICK SYMPTOM RELIEF TO AUGMENT GROWTH
6.4 URETHRAL SUPPOSITORIES
6.4.1 NEED FOR LOCALIZED, FAST-ACTING THERAPY TO CONTRIBUTE TO GROWTH

7 SUPPOSITORIES MARKET, BY BASE
7.1 INTRODUCTION
7.2 OLEAGINOUS/ LIPOPHILIC BASES
7.2.1 RISING PATIENT PREFERENCE FOR EASY-TO-USE, NON-ORAL DOSAGE FORMS TO FACILITATE GROWTH
7.3 AQUEOUS/HYDROPHILIC BASES
7.3.1 NEED TO MAINTAIN DRUG STABILITY TO SPUR GROWTH
7.4 EMULSIFYING BASES
7.4.1 CONSISTENT DRUG RELEASE AND ABSORPTION TO BOLSTER GROWTH

8 SUPPOSITORIES MARKET, BY PRESCRIPTION
8.1 INTRODUCTION
8.2 PRESCRIBED SUPPOSITORIES
8.2.1 INCREASED RELIANCE ON PRESCRIPTION SUPPOSITORIES FOR HORMONE REPLACEMENT AND ANTIEMETIC TREATMENT TO SUPPORT GROWTH
8.3 OVER-THE-COUNTER SUPPOSITORIES
8.3.1 GROWING PREFERENCE FOR CONVENIENT, NON-INVASIVE RELIEF FROM COMMON HEALTH CONCERNS TO FUEL MARKET

9 SUPPOSITORIES MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 HEMORRHOID TREATMENTS
9.2.1 INCREASING OBESITY AND SEDENTARY LIFESTYLE TO EXPEDITE GROWTH
9.3 ANTI-BACTERIAL AND ANTI-FUNGAL APPLICATIONS
9.3.1 GROWING BURDEN OF VAGINAL INFECTIONS TO PROPEL MARKET
9.4 ANALGESICS & ANTIPYRETICS
9.4.1 INCREASING INCIDENCE OF CHRONIC PAIN CONDITIONS TO ACCELERATE GROWTH
9.5 LAXATIVES
9.5.1 LOW DIETARY FIBER INTAKE AND RISING PREVALENCE OF CONSTIPATION TO BOOST MARKET
9.6 ANTI-EMETICS
9.6.1 GROWING USE OF ANTI-EMETIC SUPPOSITORIES FOR CHEMOTHERAPY, RADIATION THERAPY, OR POST-OPERATIVE RECOVERY TO DRIVE MARKET
9.7 OTHER APPLICATIONS

10 SUPPOSITORIES MARKET, BY PATIENT TYPE
10.1 INTRODUCTION
10.2 ADULT PATIENTS
10.2.1 GROWING FOCUS ON CHRONIC CONDITION MANAGEMENT TO DRIVE MARKET
10.3 PEDIATRIC PATIENTS
10.3.1 INCREASING NEED FOR ALTERNATIVE DRUG DELIVERY TO SUPPORT GROWTH
10.4 GERIATRIC PATIENTS
10.4.1 NEED FOR RELIABLE, EFFECTIVE, AND WELL-TOLERATED DRUG DELIVERY IN ELDERLY PATIENTS TO AID GROWTH

11 SUPPOSITORIES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Rising demand for non-oral therapeutics among aging and chronic patient groups to augment growth
11.2.3 CANADA
11.2.3.1 Government support and public health campaigns to encourage growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 High healthcare spending and prescription culture to support growth
11.3.3 FRANCE
11.3.3.1 Increasing use of suppositories in pediatrics, gynecology, and internal medicine to propel market
11.3.4 UK
11.3.4.1 Growing use of suppositories for pediatric fever, antiemetic needs, and constipation management to drive market
11.3.5 ITALY
11.3.5.1 Increasing pediatric patient population to contribute to growth
11.3.6 SPAIN
11.3.6.1 Rising adoption of non-invasive, self-administered dosage forms to spur growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Geriatric population and regulatory guidelines to drive market
11.4.3 CHINA
11.4.3.1 Expanding elderly population to boost market
11.4.4 INDIA
11.4.4.1 Increasing healthcare penetration across urban and semi-urban areas to promote growth
11.4.5 AUSTRALIA
11.4.5.1 Increased patient volume and favorable government initiatives to sustain growth
11.4.6 SOUTH KOREA
11.4.6.1 Favorable insurance policy to accelerate growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Expanding public healthcare access and domestic manufacturing to bolster growth
11.5.3 MEXICO
11.5.3.1 Growing consumer preference for self-medication to propel market
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2 GCC COUNTRIES
11.6.2.1 Kingdom of Saudi Arabia (KSA)
11.6.2.1.1 Substantial public healthcare investment to facilitate growth
11.6.2.2 United Arab Emirates (UAE)
11.6.2.2.1 Favorable environment for drug import and local manufacturing to aid growth
11.6.2.3 Rest of GCC Countries
11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SUPPOSITORIES MARKET
12.3 REVENUE ANALYSIS, 2022-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 BRAND/PRODUCT COMPARISON
12.6 COMPANY VALUATION AND FINANCIAL METRICS
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Type footprint
12.7.5.4 Base footprint
12.7.5.5 Prescription footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 SANDOZ GROUP AG
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 MnM view
13.1.1.3.1 Key strengths
13.1.1.3.2 Strategic choices
13.1.1.3.3 Weaknesses and competitive threats
13.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 MnM view
13.1.2.3.1 Key strengths
13.1.2.3.2 Strategic choices
13.1.2.3.3 Weaknesses and competitive threats
13.1.3 CIPLA
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 MnM view
13.1.3.3.1 Key strengths
13.1.3.3.2 Strategic choices
13.1.3.3.3 Weaknesses and competitive threats
13.1.4 SANOFI
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Deals
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 BAYER AG
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Expansions
13.1.7 NOVARTIS AG
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Deals
13.1.8 ZYDUS GROUP
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product approvals
13.1.9 BLISS GVS PHARMA LIMITED
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.10 CHURCH & DWIGHT CO., INC.
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.11 BAUSCH HEALTH COMPANIES INC.
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.12 ADCOCK INGRAM
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.13 ASPEN HOLDINGS
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.14 JULPHAR
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.15 HALEON GROUP OF COMPANIES
13.1.15.1 Business overview
13.1.15.2 Products offered
13.1.16 LES LABORATOIRES SERVIER
13.1.16.1 Business overview
13.1.16.2 Products offered
13.1.17 PRESTIGE CONSUMER HEALTHCARE INC.
13.1.17.1 Business overview
13.1.17.2 Products offered
13.1.18 VIATRIS INC.
13.1.18.1 Business overview
13.1.18.2 Products offered
13.1.19 GALEN LIMITED
13.1.19.1 Business overview
13.1.19.2 Products offered
13.1.20 MERIDIAN ENTERPRISES PVT. LTD.
13.1.20.1 Business overview
13.1.20.2 Products offered
13.2 OTHER PLAYERS
13.2.1 COSETTE PHARMACEUTICALS
13.2.2 FLAGSHIP
13.2.3 OUBARI PHARMA
13.2.4 LAVINA PHARMACEUTICALS PVT. LTD.
13.2.5 NORWELL

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS